Apollo Hospitals Enterprise Limited — PPTs, 06-11-2025: Investor Presentation

Here's a concise summary for retail investors:

**Business Performance:**

Consolidated revenue for Q2 FY26 climbed 13% YoY to ₹6,303.5 Cr. Healthcare Services revenue grew 9% to ₹3,169 Cr, driven by a 9% rise in average revenue per inpatient and strong CONGO specialty growth. Diagnostics & Retail Health (AHLL) revenue jumped 17% to ₹473.9 Cr, while Apollo HealthCo (Digital Health & Pharmacy) revenue increased 17% to ₹2,660.6 Cr.

**Growth Drivers or Strategy:**

The company plans a significant expansion in Healthcare Services, adding ~3,600 census beds over the next five years, with a total project cost of ~₹8,300 Cr. Apollo HealthCo is focused on enhancing its omnichannel platform, improving pharmacy order economics, driving new user acquisition, and expanding diagnostic reach.

**Recent Developments:**

Hospitals achieved milestones of over 51 lakh surgeries and 27,000 organ transplants, including India’s first robotic telesurgery for colorectal cancer. AHLL expanded its diagnostic test menu and introduced new pain relief therapies. Apollo HealthCo announced a composite demerger and amalgamation scheme, with the new entity expected to list as an 'Indian Owned and Controlled Company' by Q4 FY27.

**Key Financial Metrics:**

Q2 FY26 Consolidated EBITDA grew 15% to ₹941.2 Cr, and PAT surged 26% to ₹477.2 Cr. Apollo HealthCo's Q2 FY26 PAT saw a four-fold increase to ₹73.4 Cr, recording its lowest cash loss of ₹38.6 Cr. Its Platform GMV expanded 16% to ₹723 Cr.

**Management Commentary / Outlook:**

Management anticipates achieving a ₹25,000 Cr run-rate annualized revenue with a 7% EBITDA margin by Q4 FY27, underscoring confidence in strategic initiatives and operational efficiency.